(redirected from Autologous Stem Cell Transplant)
ASCTAutologous Stem Cell Transplant
ASCTApplied Science Technologist
ASCTAmerican Society for Cytotechnology (Raleigh, NC)
ASCTAmerican Society of Canine Trainers (est. 1994)
ASCTAdvanced Semi-solid Casting Technology (Madison-Kipp)
ASCTAkademischer Skiclub Tübingen (Tübingen, Germany)
ASCTAcetate:Succinate CoA-Transferase
ASCTAgent du Service Commercial Train
ASCTAuxiliary Satellite Control Terminal
ASCTAncillary Satellite Control Terminal
ASCTAssociation for Safe and Competitive Trucking
ASCTAmerican Society of Computing Technicians
ASCTAssociate of the Society of Cardiopulmonary Technology (New Zealand)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
He was diagnosed with MM and was treated with five cycles of Cyclophosphamide, Bortezomib, and Dexamethasone (CYBOR-D) prior to undergoing an autologous stem cell transplant (ASCT).
Indeed, there are reports that the immunomodulatory agents (IMiDs) lenalidomide and pomalidomide inhibit proliferation and function of regulatory T-cells (Tregs), which may then be incapable of regulating the immune response in those receiving autologous stem cell transplants [4].
Seattle Genetics, Inc., Bothell, WA, announced the US Food and Drug Administration (FDA) has granted accelerated approval ofAdcetris (brentuximab vedotin) for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen.
Says Dr Muhanna, a€?Autologous stem cell collection (The autologous stem cell transplant involves relocation of cells from the patienta€™s own blood) and transplantation unit will also be initiated by the year-end or beginning of 2011 once the expansion of the National Oncology Centre has been completed.a€™
Autologous stem cell transplant or bone marrow transplant.
Jean-Luc Harousseau, of Hospital Hotel-Dieu, Nantes, France, a complete response or a very good partial response following autologous stem cell transplant is associated with improved event-free and overall survival.
Mozobil, currently in Phase 3 trials, has been shown in multiple earlier studies to rapidly increase the number of stem cells in circulation in the blood, an important step in preparing a patient for an allogeneic or autologous stem cell transplant. Increasing the number of stem cells collected can improve patient outcomes in two ways: by helping patients who were previously not eligible to meet the target ranges needed for a transplant and by raising the level of stem cells collected in those already eligible, which would improve the viability of the transplant.
Exactly how can scientists answer the question, "What are the odds that a child will require an autologous transplant in his or her life time?" We know that if a child were to develop a malignancy later in life, an autologous stem cell transplant would not be the first choice of therapeutic modality, as there would be no way to ensure that the stem cells did not contain this same malignant and/or clonal abnormality.
Mr Laurie underwent a procedure called autologous stem cell transplant which involves extracting immature bone marrow cells - the stem cells - from his own blood.
The CHMP positive opinion for REVLIMID was based on the data from SWOG S0777, a phase three trial assessing the triplet combination of REVLIMID, bortezomib and dexamethasone (RVd) in adult patients with earlier untreated multiple myeloma, without an intent for immediate autologous stem cell transplant. Results from SWOG S0777 indicated statistically significant progression-free and overall survival improvements in patients treated with RVd compared to those treated with REVLIMID and dexamethasone alone.
Reportedly, this application seeks to broaden the existing marketing authorisation for daratumumab (DARZALEX) to include use in combination with bortezomib, thalidomide and dexamethasone (VTD) as treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant (ASCT).
Full browser ?